Viralytics Limited (VLA) is pleased to announce that it has received notice of a decision to grant a patent in Japan involving the use of Coxsackie A viruses including CAVATAKTM in the treatment of multiple myeloma. Japan is the world’s third largest pharmaceutical market behind the US and Europe, and multiple myeloma is an important blood cancer for which the patient prognosis is exceptionally poor, so the medical need is large. Specifically the patent covers the use of a pharmaceutical composition of any of the Coxsackieviruses A13, A15, A18, A20 and A21 in treating multiple myeloma. CAVATAKTM is Coxsackievirus A21.
Viralytics is listed on the Australian Stock Exchange (VLA), Viralytics’ principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology. CAVATAKTM is the trade name for Viralytics’ proprietary formulation of the Coxsackievirus Type A21 (CVA21). EVATAKTM is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1 (EV1). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of cells, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion